Browsing by Author "Alacacıoğlu, Ahmet"
Now showing items 1-10 of 10
-
Evaluation of prognostic factors and adjuvant chemotherapy in patients with small bowel adenocarcinoma who underwent curative resection
Aydın, Dinçer; Şendur, Mehmet Ali; Kefeli, Umut; Ünal, Ölçün Ümit; Taştekin, Didem; Akyol, Murat; Tanrıkulu, Eda; Çiltaş, Aydın; Ustaalioğlu, Başak Bala; Uysal, Mükremin; Esbağ, Onur; Yazılıtaş, Doğan; Tanrıverdi, Özgür; Bilici, Ahmet; Arpacı, Erkan; Berk, Veli; Yetişyiğit, Tarkan; Özdemir, Nuriye Yıldırım; Öztop, İlhan; Alacacıoğlu, Ahmet; Aydın, Özhan; Özçelik, Melike; Yıldırım, Emre; Dinç, Nur; Gümüş, Mahmut (Cıg Media Group, LP, 2017)This is a multicenter study to assess the prognostic factors and adjuvant chemotherapy in patients with small bowel adenocarcinoma (SBA). A total of 78 patients with SBA diagnosed with completely resected SBA were involved ... -
Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?
Solmaz, Şerife; Uzun, Özcan; Acar, Celal; Sevindik, Ömür Gökmen; Pişkin, Özden; Özsan, Hayri Güner; Demirkan, Fatih; Ündar, Bülent; Alacacıoğlu, Ahmet; Özcan, Mehmet Ali; Alacacıoğlu, İnci (Wolters Kluwer Medknow Publications, 2018)BACKGROUND: Recent reports showed neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), as a predictor of progression-free survival (PFS) and overall survival ... -
Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results
Esin, Ece; Çakmak Öksüzoğlu, Ömür Berna; Bilici, Ahmet; Çiçin, İrfan; Aksoy, Sercan; Alacacıoğlu, Ahmet; Kaplan, Mehmet Ali; Çabuk, Devrim; Sümbül, Ahmet Taner; Paydaş, Semra; Sakin, Ayşegül; Korkmaz, Tuba; Özdemir Yıldırım, Nuriye; Artaç, Mehmet; Harputluoğlu, Hakan; Yumuk, Perran Fulden; Atalay Başaran, Gül; Oyan Uluç, Başak; Demirci, Umut (Oxford University Press, 2018)... -
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: Real-life practice outcomes
Esin, Ece; Çakmak Öksüzoǧlu, Berna; Bilici, Ahmet Erkan; Çiçin, İrfan; Köstek, Osman; Kaplan, Mehmet Ali; Aksoy, Sercan; Aktaş, Burak Yasin; Özdemir, Özlem; Alacacıoğlu, Ahmet; Çabuk, Devrim; Sümbül, Ahmet Taner; Sakin, Abdullah; Paydaş, Semra; Yetişir, Ersin; Er, Özlem; Korkmaz, Taner; Yıldırım, Nilgün; Şakalar, Teoman; Demir, Hacer; Artaç¸, Mehmet; Karaaǧaç, Mustafa; Harputluoǧlu, Hakan; Bilen, Ebru; Erdur, Erkan; Deǧirmencioǧlu, Serkan; Aliyev, Altay; Çil, Timuçin; Olgun, Polat; Başaran, Gül Atalay; Gümüşay, Özge; Demir, Atakan; Tanrıkulu, Eda; Yumuk, Perran Fulden; İmamoğlu, İnanç; Oyan, Başak; Çetin, Bülent Eren; Haksöyler, Veysel; Karadurmuş, Nuri; Ertürk, İsmail; Evrensel, Türkkan; Yılmaz, Hasan; Beypınar, İsmail; Koçer, Murat; Pilancı, Kezban Nur; Şeker, Mesut Metin; Ürün, Yüksel; Yıldırım, Nuriye O.; Eren, Tülay; Demirci, Umut (Springer, 2019)PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study ... -
Platelet parameters in lung cancer patients
Karagöz, Bülent; Alacacıoğlu, Ahmet; Bilgi, Oğuz; Demirci, Hakan Gökalp; Özgün, Alpaslan; Akyol Erikci, Alev; Sayan, Özkan; Yılmaz, Bahattin; Kandemir, Emin Gökhan (Lippincott Williams & Wilkins, 2014)... -
Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study
Artaç, Mehmet; Çubukçu, Erdem; Bozkurt, Oktay; Bilici, Ahmet; Çelik, S.; Özçelik, M.; Öven, B.; Şimşek, E.; Geredeli, C.; Karaca, M.; Cil, T.; Harputluoğlu, Hakan; Şendur, Mehmet Ali Nahit; Türk, H. Mehmet; Kefeli, Umut; Alacacıoğlu, Ahmet; Tural, D.; Sakin, A.; Karadurmuş, Nuri; Çevik, Duygu; Dane, Faysal; Gümüş, Mahmut (Elsevier, 2022)Background: Randomized clinical trials showed that maintenance chemotherapy plus biologics in patients with mCRC could increase the progression free survival (PFS) without any advantage for overall survival (OS). Our aim ... -
Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer
Kefeli, Umut; Arslan, Çağatay; Yıldırım, Mahmut Emre; Işıkdoğan, Abdurrahman; Karadurmuş, Nuri; Karabulut, Bülent; Çubukçu, Erdem; Çiçin, İrfan; Yalçın, Şuayib; Türk, Hacı Mehmet; Bilir, Cemil; Karaca, Mustafa; Artaç, Mehmet; Şendur, Mehmet Nahit; Alacacıoğlu, Ahmet; Tanrıkulu Şimşek, Eda; Dane, Faysal; Bilici, Ahmet; Çevik, Duygu; Gümüş, Mahmut (Lippincott Williams & Wilkins, 2021)Background: Efficacy of anti-angiogenic and anti-EGFR agents has been demonstrated metastatic colorectal cancer (mCRC). Real-world evidence is especially important to detect the findings of patients outside of clinical ... -
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC
Yıldırım, Mahmut Emre; Karaca, Mustafa; Artaç, Mehmet; Çiçin, İrfan; Geredeli, Çağlayan; Alacacıoğlu, Ahmet; Tanrıkulu Şimşek, Eda; Bilici, Ahmet; Harputluoğlu, Hakan; Özçelik, Melike; Bozkurt, Oktay; Yüksel, Sinemiş; Tural, Deniz; Sakin, Abdullah; Çil, Timuçin; Öven, Bala Başak; Dane, Faysal; Çevik, Duygu; Gümüş, Mahmut; Işıkdogan, Abdurrahman (Lippincott Williams and Wilkins, 2022)... -
Thrombin activatable fibrinolysis inhibitor, tissue factor pathway inhibitor, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer
Salman, Tarık; Bilici, Ahmet; Arslan, Çağatay; Varol, Umut; Yıldız, İbrahim; Akyol, Murat; Yıldız, Yaşar; Küçükzeybek, Yüksel; Alacacıoğlu, Ahmet; Yılmaz, Uğur (American Society of Clinical Oncology, 2016)...
